LEVOFLOXACIN

Course overview

LEVOFLOXACIN IS FDA-APPROVED FOR THE TREATMENT OF NOSOCOMIAL PNEUMONIA, COMMUNITY-ACQUIRED PNEUMONIA, ACUTE BACTERIAL RHINOSINUSITIS, ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS, ACUTE BACTERIAL PROSTATITIS, ACUTE PYELONEPHRITIS, URINARY TRACT INFECTION, SKIN OR SKIN STRUCTURE INFECTIONS, PROPHYLAXIS AND TREATMENT OF PLAQUE DUE TO YERSINIA PESTIS, AND TO REDUCE THE INCIDENCE OF DISEASE PROGRESSION OF INHALATIONAL ANTHRAX. IT IS IN THE FLUOROQUINOLONE CLASS OF MEDICATIONS. THIS ACTIVITY WILL HIGHLIGHT THE INDICATIONS, MECHANISM OF ACTION, ADVERSE EVENT PROFILE, CONTRAINDICATION, MONITORING, TOXICITY, AND RELEVANT INTERACTIONS PERTINENT FOR MEMBERS OF THE HEALTHCARE TEAM IN THE TREATMENT OF PATIENTS WITH BACTERIAL INFECTIONS.